Amgen Stock Price, News & Analysis (NASDAQ:AMGN)

$177.04 2.12 (1.21 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$177.04
Today's Range$174.14 - $177.41
52-Week Range$145.12 - $191.10
Volume5.24 million shs
Average Volume3.21 million shs
Market Capitalization$128.76 billion
P/E Ratio14.1
Dividend Yield2.59%
Beta1.36

About Amgen (NASDAQ:AMGN)

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AMGN
CUSIP03116210
Phone805-447-1000

Debt

Debt-to-Equity Ratio1.05%
Current Ratio6.07%
Quick Ratio5.72%

Price-To-Earnings

Trailing P/E Ratio14.1
Forward P/E Ratio13.98
P/E Growth2.57

Sales & Book Value

Annual Sales$22.99 billion
Price / Sales5.59
Cash Flow$14.61 per share
Price / Cash12.12
Book Value$40.16 per share
Price / Book4.41

Profitability

Trailing EPS$11.05
Net Income$7.72 billion
Net Margins35.54%
Return on Equity29.90%
Return on Assets11.80%

Miscellaneous

Employees19,200
Outstanding Shares725,910,000

Amgen (NASDAQ:AMGN) Frequently Asked Questions

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Tuesday, December 12th. Stockholders of record on Thursday, February 15th will be given a dividend of $1.32 per share on Thursday, March 8th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Amgen's previous quarterly dividend of $1.15. View Amgen's Dividend History.

How will Amgen's stock buyback program work?

Amgen announced that its board has initiated a stock repurchase program on Thursday, October 26th 2017, which allows the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's management believes its stock is undervalued.

How were Amgen's earnings last quarter?

Amgen, Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Wednesday, October, 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $3.11 by $0.16. The medical research company earned $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The company's revenue for the quarter was down .7% on a year-over-year basis. During the same quarter last year, the business earned $3.02 EPS. View Amgen's Earnings History.

When will Amgen make its next earnings announcement?

Amgen is scheduled to release their next quarterly earnings announcement on Thursday, February, 1st 2018. View Earnings Estimates for Amgen.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY17 earnings guidance on Wednesday, October, 25th. The company provided earnings per share guidance of $12.50-12.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $12.56. The company issued revenue guidance of $22.7-23 billion, compared to the consensus revenue estimate of $22.86 billion.

Where is Amgen's stock going? Where will Amgen's stock price be in 2017?

19 brokers have issued 12-month price targets for Amgen's stock. Their forecasts range from $161.00 to $210.00. On average, they anticipate Amgen's stock price to reach $190.89 in the next year. View Analyst Ratings for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:

  • 1. Cann analysts commented, "Amgen yesterday announced that the New England Journal of Medicine (NEJM) published positive results from the six-month phase III STRIVE study evaluating Aimovig (erenumab) versus placebo for the prevention of episodic migraine (between four and 14 migraine days per month). The NEJM article reported that Aimovig delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints in the study." (11/30/2017)
  • 2. Argus analysts commented, "We would consider a more constructive stance on AMGN on signs of stronger contributions from the company's new drug pipeline or from its biosimilars portfolio," the firm said."We note, however, that Amgen may not generate commercial revenue from biosimilars until 2019 due to regulatory and legal hurdles." (11/1/2017)
  • 3. According to Zacks Investment Research, "Amgen beat expectations for both earnings and sales in Q3 and raised its earnings guidance for 2017. However sales declined year over year. Meanwhile sales of key drug Repatha disappointed in the quarter. Amgen’s newer drugs – Prolia, Xgeva, Vectibix and Sensipar – are performing well. Amgen is also progressing with its pipeline including biosimilar drugs. Amgen’s shares have outperformed the industry this year so far. However, Amgen has some challenges in store, given the presence of biosimilar competition and slowdown in sales of mature drugs. Volume growth of new drugs may not be enough to offset the lost sales due to the decline in mature brands. While Neupogen is already facing U.S. biosimilar competition, Neulasta and Epogen could start facing the same next year. Also the softness in Enbrel sales due to stiff competitive pressure is a key cause for concern. Meanwhile, uptake of Repatha has been slow." (10/30/2017)
  • 4. Mizuho analysts commented, "We are increasing our AMGN price target from $183 to $198 on the back of the biotech sector having re-rated somewhat post the GILD/KITE acquisition. We have not changed our estimates." (9/28/2017)

Who are some of Amgen's key competitors?

Who are Amgen's key executives?

Amgen's management team includes the folowing people:

  • Robert A. Bradway, Chairman of the Board, President, Chief Executive Officer (Age 54)
  • David W. Meline, Executive Vice President, Chief Financial Officer (Age 60)
  • Sean E. Harper, Executive Vice President - Research and Development (Age 54)
  • Anthony C. Hooper, Executive Vice President - Global Commercial Operations (Age 62)
  • Brian M. McNamee, Executive Vice President - Full Potential Initiatives (Age 60)
  • Esteban Santos, Executive Vice President, Operations (Age 49)
  • Cynthia M. Patton, Senior Vice President, Chief Compliance Officer (Age 55)
  • Jonathan P. Graham, Senior Vice President, General Counsel, Secretary (Age 56)
  • Lori A. Johnston, Senior Vice President (Age 52)
  • David A. Piacquad, Senior Vice President - Business Development (Age 60)

Who owns Amgen stock?

Amgen's stock is owned by many different of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (1.12%), Nordea Investment Management AB (0.87%), Legal & General Group Plc (0.52%), Janus Henderson Group PLC (0.44%), Schwab Charles Investment Management Inc. (0.44%) and Swiss National Bank (373,642.46%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton, David Baltimore, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.

Who sold Amgen stock? Who is selling Amgen stock?

Amgen's stock was sold by a variety of institutional investors in the last quarter, including Flossbach Von Storch AG, Nordea Investment Management AB, Janus Henderson Group PLC, American Century Companies Inc., CI Global Investments Inc., First Eagle Investment Management LLC, State of Tennessee Treasury Department and Ameriprise Financial Inc.. Company insiders that have sold Amgen company stock in the last year include Carbonnel Francois De, Cynthia M Patton and Sean E Harper. View Insider Buying and Selling for Amgen.

Who bought Amgen stock? Who is buying Amgen stock?

Amgen's stock was purchased by a variety of institutional investors in the last quarter, including Stifel Financial Corp, Public Employees Retirement Association of Colorado, SG Americas Securities LLC, Schwab Charles Investment Management Inc., Pictet Asset Management Ltd., Amundi Pioneer Asset Management Inc., Jennison Associates LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Amgen.

How do I buy Amgen stock?

Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of Amgen stock can currently be purchased for approximately $177.04.

How big of a company is Amgen?

Amgen has a market capitalization of $128.76 billion and generates $22.99 billion in revenue each year. The medical research company earns $7.72 billion in net income (profit) each year or $11.05 on an earnings per share basis. Amgen employs 19,200 workers across the globe.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]


MarketBeat Community Rating for Amgen (AMGN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,006 (Vote Outperform)
Underperform Votes:  619 (Vote Underperform)
Total Votes:  1,625
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amgen (NASDAQ:AMGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.392.432.482.48
Ratings Breakdown: 0 Sell Rating(s)
14 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
14 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
13 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
11 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $189.89$189.68$186.74$181.90
Price Target Upside: 8.56% upside8.25% upside1.44% downside10.32% upside

Amgen (NASDAQ:AMGN) Consensus Price Target History

Price Target History for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/15/2017Goldman Sachs GroupDowngradeConviction-Buy -> BuyHighView Rating Details
12/12/2017OppenheimerSet Price TargetBuy$205.00LowView Rating Details
11/30/2017CannReiterated RatingBuy$205.00HighView Rating Details
11/1/2017ArgusDowngradeBuy -> Hold$175.22 -> $195.00N/AView Rating Details
10/29/2017MizuhoSet Price TargetBuy$198.00N/AView Rating Details
10/26/2017BMO Capital MarketsReiterated RatingMarket Perform$198.00N/AView Rating Details
10/26/2017Morgan StanleyLower Price TargetOverweight$196.00 -> $193.00N/AView Rating Details
10/26/2017Royal Bank of CanadaLower Price TargetSector Perform$192.00 -> $188.00N/AView Rating Details
10/13/2017BarclaysBoost Price TargetEqual Weight$180.00 -> $190.00N/AView Rating Details
10/5/2017Bank of AmericaBoost Price TargetBuy$210.00N/AView Rating Details
9/29/2017Credit Suisse GroupReiterated RatingNeutral$177.00 -> $186.00MediumView Rating Details
9/25/2017Jefferies GroupReiterated RatingBuy$200.00LowView Rating Details
7/26/2017Deutsche BankReiterated RatingHold$172.00 -> $174.00LowView Rating Details
7/22/2017CowenReiterated RatingOutperform$209.00LowView Rating Details
6/26/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/22/2017Leerink SwannReiterated RatingMarket Perform$161.00LowView Rating Details
6/8/2017Sanford C. BernsteinSet Price TargetHold$164.00MediumView Rating Details
4/28/2017Robert W. BairdReiterated RatingNeutral$165.00LowView Rating Details
3/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$193.00LowView Rating Details
12/13/2016Chardan CapitalUpgradeSell -> NeutralN/AView Rating Details
9/28/2016CitigroupLower Price TargetNeutral$175.00 -> $172.00N/AView Rating Details
9/28/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
8/26/2016GabelliInitiated CoverageHoldN/AView Rating Details
2/23/2016BTIG ResearchReiterated RatingSell$135.00N/AView Rating Details
1/22/2016Wells Fargo & CompanyReiterated RatingHoldN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$202.00N/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Amgen (NASDAQ:AMGN) Earnings History and Estimates Chart

Earnings by Quarter for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ AMGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2018$3.02N/AView Earnings Details
10/25/2017Q3 2017$3.11$3.27$5.75 billion$5.77 billionViewN/AView Earnings Details
7/25/2017Q2 2017$3.11$3.27$5.67 billion$5.81 billionViewN/AView Earnings Details
4/26/2017Q1 2017$3.00$3.15$5.60 billion$5.46 billionViewN/AView Earnings Details
2/2/2017Q416$2.79$2.89$5.75 billion$5.97 billionViewListenView Earnings Details
10/27/2016Q316$2.79$3.02$5.73 billion$5.81 billionViewListenView Earnings Details
7/27/2016Q216$2.74$2.84$5.58 billion$5.69 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.07$2.48$4.91 billion$5.03 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Amgen (NASDAQ:AMGN) Earnings Estimates

2017 EPS Consensus Estimate: $12.28
2018 EPS Consensus Estimate: $12.90
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$3.04$3.17$3.09
Q2 20173$3.05$3.12$3.09
Q3 20173$3.01$3.19$3.12
Q4 20173$2.93$3.03$2.97
Q1 20182$3.27$3.30$3.29
Q2 20182$3.08$3.41$3.25
Q3 20182$3.18$3.29$3.24
Q4 20182$3.13$3.13$3.13
(Data provided by Zacks Investment Research)

Dividends

Amgen (NASDAQ:AMGN) Dividend Information

Next Dividend:3/8/2018
Annual Dividend:$4.60
Dividend Yield:2.60%
Dividend Growth:28.60% (3 Year Average)
Payout Ratio:41.63% (Trailing 12 Months of Earnings)
36.33% (Based on This Year's Estimates)
36.19% (Based on Next Year's Estimates)
Track Record:6 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/12/2017quarterly$1.322.98%2/14/20182/15/20183/8/2018
10/24/2017quarterly$1.152.59%11/16/201711/17/201712/8/2017
7/28/2017quarterly$1.152.64%8/15/20178/17/20179/8/2017
3/7/2017quarterly$1.152.59%5/15/20175/17/20176/8/2017
12/20/2016quarterly$1.153.15%2/13/20172/15/20173/8/2017
10/14/2016quarterly$1.002.46%11/14/201611/16/201612/8/2016
7/22/2016quarterly$1.002.4%8/15/20168/17/20169/8/2016
3/2/2016quarterly$1.002.74%5/13/20165/17/20166/8/2016
12/15/2015quarterly$1.002.43%2/11/20162/16/20163/8/2016
10/14/2015quarterly$0.792.07%11/12/201511/16/201512/7/2015
7/28/2015quarterly$0.791.84%8/13/20158/17/20159/8/2015
3/4/2015quarterly$0.791.98%5/12/20155/14/20156/5/2015
12/17/2014quarterly$0.791.88%2/10/20152/12/20153/6/2015
10/17/2014quarterly$0.611.77%11/10/201411/13/201412/5/2014
7/25/2014quarterly$0.611.99%8/12/20148/14/20149/5/2014
3/5/2014quarterly$0.611.96%5/13/20145/15/20146/6/2014
12/13/2013quarterly$0.612.18%2/11/20142/13/20143/7/2014
10/16/2013quarterly$0.471.62%11/12/201311/14/201312/6/2013
7/26/2013quarterly$0.471.72%8/14/20138/16/20139/6/2013
3/6/2013quarterly$0.472.02%5/14/20135/16/20136/7/2013
12/13/2012quarterly$0.472.11%2/11/20132/13/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Amgen (NASDAQ AMGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 78.62%
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)
Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ AMGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/12/2017Sean E HarperEVPSell1,525$176.83$269,665.75View SEC Filing  
11/13/2017Sean E HarperEVPSell1,525$171.58$261,659.50View SEC Filing  
11/8/2017Carbonnel Francois DeDirectorSell4,000$173.61$694,440.00View SEC Filing  
10/9/2017Sean E HarperEVPSell1,525$185.95$283,573.75View SEC Filing  
5/24/2017Cynthia M PattonSVPSell2,922$154.40$451,156.80View SEC Filing  
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.00View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.52View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.25View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.00View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.30View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.90View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.25View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.00View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.12View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amgen (NASDAQ AMGN) News Headlines

Source:
DateHeadline
Amgen, Inc. breached its 50 day moving average in a Bearish Manner : AMGN-US : December 15, 2017Amgen, Inc. breached its 50 day moving average in a Bearish Manner : AMGN-US : December 15, 2017
finance.yahoo.com - December 15 at 3:23 PM
Amgen: Why Goldman Just Wants to Be FriendsAmgen: Why Goldman Just Wants to Be Friends
finance.yahoo.com - December 15 at 3:23 PM
Amgen (AMGN) Lowered to "Buy" at Goldman Sachs GroupAmgen (AMGN) Lowered to "Buy" at Goldman Sachs Group
www.americanbankingnews.com - December 15 at 9:04 AM
AMGN Dividend Yield Pushes Past 3% - NasdaqAMGN Dividend Yield Pushes Past 3% - Nasdaq
www.nasdaq.com - December 15 at 7:01 AM
Amgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentralAmgen Teams Up With Cambridge Biotech Community To Select Two Startups To Receive Golden Tickets At LabCentral
finance.yahoo.com - December 15 at 7:01 AM
Biopharma wins in Trump tax billBiopharma wins in Trump tax bill
finance.yahoo.com - December 13 at 3:22 PM
Amgen: Even Biotech Stocks Boost Their DividendsAmgen: Even Biotech Stocks Boost Their Dividends
finance.yahoo.com - December 13 at 3:22 PM
$5.85 Billion in Sales Expected for Amgen, Inc. (AMGN) This Quarter$5.85 Billion in Sales Expected for Amgen, Inc. (AMGN) This Quarter
www.americanbankingnews.com - December 13 at 12:06 PM
Amgen Announces 15 Percent Increase In 2018 First Quarter DividendAmgen Announces 15 Percent Increase In 2018 First Quarter Dividend
finance.yahoo.com - December 13 at 7:11 AM
Sean E. Harper Sells 1,525 Shares of Amgen, Inc. (AMGN) StockSean E. Harper Sells 1,525 Shares of Amgen, Inc. (AMGN) Stock
www.americanbankingnews.com - December 12 at 11:22 PM
Amgen, Inc. (AMGN) Announces Quarterly Dividend of $1.32Amgen, Inc. (AMGN) Announces Quarterly Dividend of $1.32
www.americanbankingnews.com - December 12 at 5:52 PM
Jim Simons: Pioneer Quant ManagerJim Simons: Pioneer Quant Manager
finance.yahoo.com - December 12 at 3:21 PM
Amgens Kyprolis extends overall survival in blood cancer patients - Seeking AlphaAmgen's Kyprolis extends overall survival in blood cancer patients - Seeking Alpha
seekingalpha.com - December 12 at 7:22 AM
Feeble Industry Group Rank Hamper Amgen (AMGN) Rating - Investorplace.comFeeble Industry Group Rank Hamper Amgen (AMGN) Rating - Investorplace.com
investorplace.com - December 12 at 7:22 AM
Amgens Kyprolis improves overall survival in blood cancer patientsAmgen's Kyprolis improves overall survival in blood cancer patients
finance.yahoo.com - December 12 at 7:22 AM
KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE TrialKYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial
finance.yahoo.com - December 12 at 7:22 AM
Amgens Kyprolis extends overall survival in blood cancer patientsAmgen's Kyprolis extends overall survival in blood cancer patients
seekingalpha.com - December 11 at 7:27 PM
Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California WildfiresAmgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires
finance.yahoo.com - December 11 at 3:21 PM
Feeble Industry Group Rank Hamper Amgen (AMGN) RatingFeeble Industry Group Rank Hamper Amgen (AMGN) Rating
investorplace.com - December 11 at 11:46 AM
 Brokerages Expect Amgen, Inc. (AMGN) to Post $3.02 EPS Brokerages Expect Amgen, Inc. (AMGN) to Post $3.02 EPS
www.americanbankingnews.com - December 11 at 1:26 AM
Deciphering Wall Streets Differing Views of AmgenDeciphering Wall Street's Differing Views of Amgen
finance.yahoo.com - December 10 at 3:23 PM
Coherus BioSciences (CHRS) Provides Update on Litigation vs Amgen (AMGN) - StreetInsider.comCoherus BioSciences (CHRS) Provides Update on Litigation vs Amgen (AMGN) - StreetInsider.com
www.streetinsider.com - December 9 at 7:14 AM
Dec. 7 Forum Update: "Retail Sector" EditionDec. 7 Forum Update: "Retail Sector" Edition
finance.yahoo.com - December 8 at 3:21 PM
New Data To Be Presented At ASH 2017 Underscore Amgens Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood CancersNew Data To Be Presented At ASH 2017 Underscore Amgen's Commitment To Improving Lives And Changing Outcomes For Patients With Difficult-To-Treat Blood Cancers
finance.yahoo.com - December 7 at 3:23 PM
Amgen To Webcast Investor Call At ASH 2017Amgen To Webcast Investor Call At ASH 2017
www.prnewswire.com - December 6 at 4:28 PM
Amgen, Inc. – Value Analysis (NASDAQ:AMGN) : December 6, 2017Amgen, Inc. – Value Analysis (NASDAQ:AMGN) : December 6, 2017
finance.yahoo.com - December 6 at 3:21 PM
Xencor (XNCR) Secures Milestone Payment from Amgen Inc. (AMGN) - StreetInsider.comXencor (XNCR) Secures Milestone Payment from Amgen Inc. (AMGN) - StreetInsider.com
www.streetinsider.com - December 6 at 7:43 AM
FY2017 EPS Estimates for Amgen, Inc. (AMGN) Increased by AnalystFY2017 EPS Estimates for Amgen, Inc. (AMGN) Increased by Analyst
www.americanbankingnews.com - December 6 at 7:34 AM
Amgens PCSK9 Inhibitor Gets FDA Nod for Stroke PreventionAmgen's PCSK9 Inhibitor Gets FDA Nod for Stroke Prevention
finance.yahoo.com - December 5 at 3:22 PM
Amgen, Inc. breached its 50 day moving average in a Bullish Manner : AMGN-US : December 5, 2017Amgen, Inc. breached its 50 day moving average in a Bullish Manner : AMGN-US : December 5, 2017
finance.yahoo.com - December 5 at 3:22 PM
Industry Group Rank Limit Amgen (AMGN) RatingIndustry Group Rank Limit Amgen (AMGN) Rating
investorplace.com - December 4 at 11:52 AM
Why Biotech Stocks May Have More UpsideWhy Biotech Stocks May Have More Upside
finance.yahoo.com - December 4 at 7:28 AM
Biocartis Group NV: Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla(TM) RAS Biomarker TestsBiocartis Group NV: Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla(TM) RAS Biomarker Tests
feeds.benzinga.com - December 4 at 1:26 AM
Amgen (AMGN) Upgraded by BidaskClub to "Sell"Amgen (AMGN) Upgraded by BidaskClub to "Sell"
www.americanbankingnews.com - December 2 at 3:22 PM
ETFs with exposure to Amgen, Inc. : December 1, 2017ETFs with exposure to Amgen, Inc. : December 1, 2017
finance.yahoo.com - December 2 at 8:48 AM
FDA Approves Amgens Repatha® (evolocumab) To Prevent Heart Attack And StrokeFDA Approves Amgen's Repatha® (evolocumab) To Prevent Heart Attack And Stroke
finance.yahoo.com - December 2 at 8:48 AM
FDA approves heart protection claims for Amgen cholesterol drugFDA approves heart protection claims for Amgen cholesterol drug
finance.yahoo.com - December 2 at 8:48 AM
5 Companies With the Best Retirement Plans5 Companies With the Best Retirement Plans
finance.yahoo.com - December 1 at 7:50 AM
Amgens (AMGN) "Buy" Rating Reiterated at OppenheimerAmgen's (AMGN) "Buy" Rating Reiterated at Oppenheimer
www.americanbankingnews.com - November 30 at 4:42 PM
Noteworthy Thursday Option Activity: HCA, AMGN, FFIVNoteworthy Thursday Option Activity: HCA, AMGN, FFIV
www.nasdaq.com - November 30 at 3:21 PM
AbbVie Stock Up More Than 30% So Far in 2H17: Heres WhyAbbVie Stock Up More Than 30% So Far in 2H17: Here's Why
www.msn.com - November 30 at 3:21 PM
Cann Reaffirms "Buy" Rating for Amgen (AMGN)Cann Reaffirms "Buy" Rating for Amgen (AMGN)
www.americanbankingnews.com - November 30 at 7:34 AM
Aimovig™ (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine PreventionAimovig™ (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention
finance.yahoo.com - November 30 at 7:22 AM
Bullish Two Hundred Day Moving Average Cross - AMGNBullish Two Hundred Day Moving Average Cross - AMGN
www.nasdaq.com - November 29 at 3:21 PM
The FDA"s Action Date on Amgen"s Repatha Is ComingThe FDA"s Action Date on Amgen"s Repatha Is Coming
finance.yahoo.com - November 28 at 3:21 PM
Drugmakers Hold Key to Puerto Ricos Future in Tax OverhaulDrugmakers Hold Key to Puerto Rico's Future in Tax Overhaul
finance.yahoo.com - November 28 at 3:21 PM
Amgen To Present At The Evercore ISI 2017 Biopharma Catalyst/Deep Dive ConferenceAmgen To Present At The Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
www.prnewswire.com - November 27 at 4:07 PM
Amgen (AMGN) a Hold on Uninspiring Industry Group Rank - Investorplace.comAmgen (AMGN) a Hold on Uninspiring Industry Group Rank - Investorplace.com
investorplace.com - November 27 at 3:18 PM
3 Big Stock Charts for Monday: Analog Devices, Inc., Amgen, Inc. and Symantec Corporation - Investorplace.com3 Big Stock Charts for Monday: Analog Devices, Inc., Amgen, Inc. and Symantec Corporation - Investorplace.com
investorplace.com - November 27 at 3:18 PM
Biotechs Celgene, Biogen May Rally Through YearendBiotechs Celgene, Biogen May Rally Through Yearend
finance.yahoo.com - November 27 at 3:18 PM

SEC Filings

Amgen (NASDAQ:AMGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amgen (NASDAQ:AMGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amgen (NASDAQ AMGN) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.